Nkarta reports Q2 2026 results, continued enrollment in autoimmune NK-cell trials

Nkarta, Inc. reported financial results for the second quarter ended June 30, 2026 on August 10, 2026. The company said enrollment continued across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level during the quarter.¹ Patients are being dosed at 4 billion cells per dose, three doses, for a total of 12 billion cells, across all indications in both trials.¹

Nkarta said that following an agreement with the FDA on outpatient dosing, it has begun administering NKX019 through an expanding network of community-based sites, with re-dosing available to patients in both trials if needed.¹ The company described outpatient dosing as underway within its network of community-based sites, which it said broadens patient access beyond those able to travel to academic medical centers.¹

The two studies, registered as Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935), are testing NKX019, a CD19-targeted CAR-NK cell therapy, in patients with autoimmune disease after lymphodepletion. The trials plan to enroll up to 12 patients per dose level per disease indication, across six conditions: systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, and primary membranous nephropathy.¹ Patients now receive three doses of NKX019 on Days 0, 3, and 7, following lymphodepletion with either fludarabine plus cyclophosphamide, or cyclophosphamide alone for patients with significant baseline cytopenia.¹

Nkarta said initial clinical data from both trials are planned for presentation at a medical conference in 2026.¹

On finances, Nkarta held $243.2 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2026.¹ The company said it expects this to fund its current operating plan into 2029.¹ Net loss for the quarter was $40.4 million, or $0.54 per basic and diluted share.¹